Arrowhead Pharmaceuticals, Inc. (ARWR)

Market Cap	3.57B
Revenue (ttm)	249.94M
Net Income (ttm)	-153.93M
Shares Out	105.85M
EPS (ttm)	-1.08
PE Ratio	n/a
Forward PE	111.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	596,046
Open	33.34
Previous Close	33.05
Day's Range	32.66 - 35.16
52-Week Range	26.81 - 84.83
Beta	1.41
Analysts	Buy
Price Target	75.95 (+125.1%)
Earnings Date	Nov 21, 2022

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Pha...

• Industry: Biotechnology
• IPO Date: Jun 16, 1993
• CEO: Christopher Anzalone
• Employees: 329
• Stock Exchange: NASDAQ
• Ticker Symbol: ARWR

Full Company Profile

Financial Performance

In 2021, ARWR's revenue was $138.29 million, an increase of 57.16% compared to the previous year's $87.99 million. Losses were -$140.85 million, 66.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is 75.95, which is an increase of 125.10% from the latest price.

Price Target

$75.95

(125.10% upside)

Analyst Consensus: Buy

Stock Forecasts